PURPOSE. The aim of this study was to evaluate the cost-effectiveness of apixaban versus other NOACs available in India (dabigatran and rivaroxaban), warfarin and aspirin for stroke prevention in atrial fibrillation from the healthcare ... N Kulkarni,S Taur,E Tichy,... - 《European Heart Jou...
Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clin Ther. 2002;24(11):1960–86;...
Patients were eligible for daycase paracentesis if their performance status was 0–2, they were not taking warfarin, did not require hospital transport, were able to wait 2–7 days for drainage and had normal platelet counts and coagulation. If patients were on subcutaneous low-molecular weight ...
Purpose: Apixaban (5 mg BID) is a factor Xa inhibitor studied in trials of stroke prevention in atrial fibrillation compared to warfarin and aspirin. Two other novel anticoagulants (NOACs) are dabigatran, a direct thrombin inhibitor (available as 150 mg BID and 110 mg BID i...
Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: Meta-analysis of randomized controlled trials: Comment Modeling new biomedical technologies and determining their expected cost is necessary before initiating formal clinical trials. This paper estimates an eco... Whitlock,P Richard,French...
Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atria... Clostridium difficile infection (CDI) represents a significant economic healthcare burden, especially the cost of recurrent disease. Fidaxomicin pro...
WarfarinAnticoagulantsTreatment OutcomeAdministration, OralModels, EconomicMarkov ChainsSelf CareTo examine the clinical effectiveness and cost-effectiveness of self-testing and self-management of oral anticoagulation treatment compared with clinic-based monitoring. Major electronic databases were searched up to ...
Warfarin efficacy data was adjusted to be reflective of the level of INR control found in Western Europe and baseline risk was adjusted to be reflective of the UK population. Economic inputs were based on unit costs from the BNF, PSSRU and NHS Reference costs and resource use was from a ...
Furthermore, in a cost-effectiveness analysis based on the HOKUSAI-VTE clinical trial data with a lifetime horizon, edoxaban was associated with 0.033 additional QALY and a low difference in costs of GBP 55 as compared to warfarin. Nonetheless, authors pointed out the necessity of using data ...